A Multicenter, Randomized, Parallel-Group, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
Latest Information Update: 15 Jun 2025
At a glance
- Drugs Bimekizumab (Primary) ; Ustekinumab
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms BE TOGETHER
- Sponsors UCB Biopharma
Most Recent Events
- 05 Jun 2024 Planned initiation date changed from 1 May 2024 to 7 Jun 2024.
- 05 Jun 2024 Status changed from not yet recruiting to recruiting.
- 24 May 2024 New trial record